C-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 8, Issue OCT, 2016, Pages

  Lindholm, Dan ^a,b   Pham, Dan D ^a,b   Cascone, Annunziata ^a   Eriksson, Ove ^a   Wennerberg, Krister ^c   Saarma, Mart ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

C Abl; Leukemia; Nilotinib; Parkin; Parkinson's disease; synuclein

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; BOSUTINIB; BREAKPOINT CLUSTER REGION PROTEIN; DASATINIB; IMATINIB; NEUROTRANSMITTER; NILOTINIB; PARKIN; PONATINIB; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3;

ALZHEIMER DISEASE; AUTOPHAGY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL GROWTH; CELL MOTILITY; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL OUTCOME; CYTOSKELETON; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENDOCYTOSIS; GENE DELETION; GENE MUTATION; HEART DISEASE; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

EID: 84997120344     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2016.00254     Document Type: Short Survey

References (48)

1. Abid, M. B., and De Mel, S. (2016). Does ponatinib cross the blood-brain barrier? Br. J. Haematol. doi: 10.1111/bjh.14222 [Epub ahead of print].
2. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., et al. (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344. doi: 10.3233/JPD-140364.
3. Brahmachari, S., Ge, P., Lee, S. H., Kim, D., Karuppagounder, S. S., Kumar, M., et al. (2016). Activation of tyrosine kinase c-Abl contributes to a-synuclein-induced neurodegeneration. J. Clin. Invest. 126, 2970-2988. doi: 10.1172/JCI85456.
4. Brundin, P., Atkin, G., and Lamberts, J. T. (2015). Basic science breaks through: new therapeutic advances in Parkinson's disease. Mov. Disord. 30, 1521-1527. doi: 10.1002/mds.26332.
5. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502. doi: 10.1038/nrd839.
6. Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., and Sulzer, D. (2004). Impaired degradation of mutant a-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295. doi: 10.1126/science.1101738.
7. Das, J., Chen, P., Norris, D., Padmanabha, R., Lin, J., Moquin, R. V., et al. (2006). 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4 pyrimidinyl]amino)]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819-6832. doi: 10.1021/jm060727j.
8. Dawson, T. M., and Dawson, V. L. (2011). Parkin plays a role in sporadic Parkinson's disease. Neurodegener. Dis. 13, 69-71. doi: 10.1159/000354307.
9. Fahn, S. (2010). Parkinson's disease: 10 years of progress, 1997-2007. Mov. Disord. 25, S2-S14. doi: 10.1002/mds.22796.
10. Gupta, A., Dawson, V. L., and Dawson, T. M. (2008). What causes cell death in Parkinson's disease. Ann. Neurol. 64, S3-S15. doi: 10.1002/ana.21573.
11. Hantschel, O., and Superti-Furga, G. (2004). Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44. doi: 10.1038/nrm1280.
12. Hebron, M. L., Lonskaya, I., and Moussa, C. E. (2013). Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of a-synuclein in Parkinson's disease models. Hum. Mol. Genet. 22, 3315-3328. doi: 10.1093/hmg/ddt192.
13. Heffron, T. P. (2016). Small molecule kinase inhibitors for the treatment of brain cancer. J. Med. Chem. doi: 10.1021/acs.jmedchem.6b00618 [Epub ahead of print].
14. Huang, W.-S., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., et al. (2010). Discovery of 3-[2-(imidazo[1, 2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-(4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl)benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem. 53, 4701-4719. doi: 10.1021/jm100395q.
15. Imam, S. Z., Trickler, W., Kimura, S., Binienda, Z. K., Paule, M. G., Slikker, W. Jr., et al. (2013). Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One 8:e65129. doi: 10.1371/journal.pone.0065129.
16. Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., et al. (2011). Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J. Neurosci. 31, 157-163. doi: 10.1523/JNEUROSCI.1833-10.2011.
17. Kalia, L. V., Kalia, S. K., and Lang, A. E. (2015). Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30, 1442-1450. doi: 10.1002/mds.26354.
18. Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., and Ko, H. S. (2014). The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci. Rep. 4:4874. doi: 10.1038/srep04874.
19. Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., et al. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1-222. doi: 10.1080/15548627.2015.1100356.
20. Ko, H. S., Lee, Y., Shin, J. H., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., et al. (2010). Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl. Acad. Sci. U S A 107, 16691-16696. doi: 10.1073/pnas.1006083107.
21. Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., et al. (2016). Current disease modifying approaches to treat Parkinson's disease. Cell. Mol. Life Sci. 73, 1365-1379. doi: 10.1007/s00018-015-2101-1.
22. Lindholm, D., Wootz, H., and Korhonen, L. (2006). ER stress and neurodegenerative diseases. Cell Death Differ. 13, 385-392. doi: 10.1038/sj.cdd.4401778.
23. Lonskaya, I., Hebron, M. L., Selby, S. T., Turner, R. S., and Moussa, C. E. (2015). Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models. Neuroscience 304, 316-327. doi: 10.1016/j.neuroscience.2015.07.070.
24. Mahul-Mellier, A. L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., et al. (2014). c-Abl phosphorylates a-synuclein and regulates its degradation: implication for a-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 23, 2858-2879. doi: 10.1093/hmg/ddt674.
25. Mudò, G., Mäkelä, J., Di Liberto, V., Tselykh, T. V., Olivieri, M., Piepponen, P., et al. (2012). Transgenic expression and activation of PGC-1a protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 69, 1153-1165. doi: 10.1007/s00018-011-0850-z.
26. Mullin, S., and Schapira, A. (2015). The genetics of Parkinson's disease. Br. Med. Bull. 114, 39-52. doi: 10.1093/bmb/ldv022.
27. Musumeci, F., Schenone, S., Brullo, C., and Botta, M. (2012). An update on dual Src/Abl inhibitors. Future Med. Chem. 4, 799-822. doi: 10.4155/fmc.12.29.
28. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. (2015). Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795-803. doi: 10.1016/S1474-4422(15)00144-1.
29. Pagan, F., Hebron, M., Valadez, E. H., Tores-Yaghi, Y., Huang, X., Mills, R. R., et al. (2016). Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J. Parkinsons Dis. 6, 503-517. doi: 10.3233/JPD-160867.
30. Patrone, C., Eriksson, O., and Lindholm, D. (2014). Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2, 256-262. doi: 10.1016/s2213-8587(13)70125-6.
31. Pinilla-Ibarz, J., Sweet, K., Emole, J., and Fradley, M. (2015). Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Anticancer Res. 35, 6355-6364.
32. Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., et al. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112, 1005-1012. doi: 10.1182/blood-2008-02-140665.
33. Putkonen, N., Kukkonen, J. P., Mudo, G., Putula, J., Belluardo, N., Lindholm, D., et al. (2011). Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus. Eur. J. Neurosci. 34, 1212-1221. doi: 10.1111/j.1460-9568.2011.07858.x.
34. Quintás-Cardama, A., and Cortes, J. (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619-1630. doi: 10.1182/blood-2008-03-144790.
35. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., et al. (2009). Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477-485. doi: 10.1038/leu.2008.334.
36. Schlatterer, S. D., Acker, C. M., and Davies, P. (2011). c-Abl in neurodegenerative disease. J. Mol. Neurosci. 45, 445-452. doi: 10.1007/s12031-011-9588-1.
37. Shah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., et al. (2008). Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493. doi: 10.1016/j.ccr.2008.11.001.
38. Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., et al. (2011). PARIS (ZNF746) repression of PGC-1a contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702. doi: 10.1016/j.cell.2011.02.010.
39. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). a-synuclein locus triplication causes Parkinson's disease. Science 302:841. doi: 10.1126/science.1090278.
40. Smith, P. D., Crocker, S. J., Jackson-Lewis, V., Jordan-Sciutto, K. L., Hayley, S., Mount, M. P., et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 100, 13650-13655. doi: 10.1073/pnas.2232515100.
41. Spillantini, M. G., and Goedert, M. (2016). Synucleinopathies: past, present and future. Neuropathol. Appl. Neurobiol. 42, 3-5. doi: 10.1111/nan.12311.
42. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). a-synuclein in Lewy bodies. Nature 388, 839-840.
43. Tanabe, A., Yamamura, Y., Kasahara, J., Morigaki, R., Kaji, R., and Goto, S. (2014). A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease. Front. Cell. Neurosci. 8:50. doi: 10.3389/fncel.2014.00050.
44. Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., and Griffin, J. D. (2006). AMN107 (nilotinib): a novel and selective inhibitor for BCR-ABL. Br. J. Cancer 94, 1765-1769. doi: 10.1038/sj.bjc.6603170.
45. Wen, Z., Shu, Y., Gao, C., Wang, X., Qi, G., Zhang, P., et al. (2014). CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease. Neurobiol. Aging 35, 2870-2880. doi: 10.1016/j.neurobiolaging.2014.05.034.
46. Winslow, A. R., and Rubinsztein, D. C. (2011). The Parkinson disease protein a-synuclein inhibits autophagy. Autophagy 7, 429-431. doi: 10.4161/auto.7.4.14393.
47. Wyse, R. K., Brundin, P., and Sherer, T. B. (2016). Nilotinib-differentiating the hope from the hype. J. Parkinsons Dis. 6, 519-522. doi: 10.3233/JPD-160904.
48. Yamamura, Y., Morigaki, R., Kasahara, J., Yokoyama, H., Tanabe, A., Okita, S., et al. (2013). Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice. Front. Cell. Neurosci. 7:12. doi: 10.3389/fncel.2013.00012.